NEWS DETAIL

Result of AGM and Resignation of Non-executive Director

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, held its Annual General Meeting (‘AGM’) today at which all resolutions were passed. Resolutions 1-15 were passed as Ordinary Resolutions and Resolutions 14 and 15 were passed as Special Resolutions.

As previously announced in September 2020, John Hartup the Senior Independent Non-Executive Director, decided not to stand for re-election at the AGM and therefore, he has resigned as a Director of the Company with effect from today, 26 November. Consequently, Anne Hyland has been appointed as the Senior Independent Director and Alan Boyd has been appointed to engage with the workforce on behalf of the board as the designated Non-Executive Director. Both of these appointments are effective from 26 November 2020.  The Nomination Committee has also started the search process for a new independent Non-Executive Director.

The voting results at the AGM are given in the table below.

  For Against Discretionary / Withheld
Resolution Number % Number % Number
1. To receive the audited financial statements and the Auditors’ and Directors’ Reports for the year ended 30 June 2020. 94,363,546 100.00% 285 0.00% 89,188
2. To approve the Directors’ Remuneration Report (other than the part containing the Directors’ remuneration policy) for the year ended 30 June 2020. 89,044,191 94.28% 5,404,286 5.72% 4,542
3. To declare a final dividend of 5.46p per share for the year ended 30 June 2020. 94,451,582 100.00% 285 00.00% 1,152
4. To re-elect Peter Allen as a Director. 82,526,572 87.38% 11,918,235 12.62% 8,212
5. To re-elect Ian Nicholson as a Director. 92,566,213 98.02% 1,866,630 1.98% 20,176
6. To re-elect Anne Hyland as a Director. 93,911,041 99.45% 521,802 0.55% 20,176
7. To re-elect Alan Boyd as a Director. 79,091,727 83.93% 15,138,298 16.07% 222,994
8. To re-elect Shaun Chilton as a Director. 93,543,054 99.04% 906,789 0.96% 3,176
9. To re-elect Nick Keher as a Director. 93,258,324 98.74% 1,191,674 1.26% 3,021
10. To reappoint PricewaterhouseCoopers LLP as auditors. 91,007,732 96.36% 3,438,680 3.64% 6,607
11. To authorise the Directors to determine the auditors’ remuneration. 91,800,589 97.20% 2,640,554 2.80% 11,876
12. To grant the Company authority to make political donations. 80,071,917 91.21% 7,715,738 8.79% 6,665,364
13. To authorise the Directors to allot shares pursuant to section 551 of the Companies Act 2006. 93,845,132 99.36% 601,552 0.64% 6,335
14. To empower the Directors to disapply pre-emption rights. 89,624,066 94.90% 4,820,119 5.10% 8,834
15. To empower the Directors to disapply pre-emption rights in relation to shares issued in connection with an acquisition or specified capital investment. 88,456,906 93.66% 5,986,979 6.34% 9,134

Note: As at 26 November 2020, Clinigen has 133,028,647 ordinary shares of 0.1 pence each in issue and the total number of voting rights is 133,028,647.

- Ends -

For further information, please contact:

Clinigen Group plc
Shaun Chilton, Group Chief Executive Officer
Nick Keher, Group Chief Financial Officer
Tel: 44 (0) 1283 495 010

J.P.Morgan Cazenove - Nominated Adviser & Joint Broker
James Mitford / Hemant Kapoor
Tel: 44 (0)20 7742 4000

RBC Capital Markets - Joint Broker
Marcus Jackson / Elliot Thomas
Tel: 44 (0)20 7653 4000

Instinctif Partners
Melanie Toyne Sewell / Phillip Marriage
Email: [email protected]
Tel: 44 (0)20 7457 2020

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and the Asia Pacific region.

Clinigen now has over 1,150 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long term growth regions. The Group works with 21 of the top 25 pharmaceutical companies; interacting with over 18,000 registered users across 115 countries, shipping approximately 6.5 million units in the year.

For more information on Clinigen, please visit www.clinigengroup.com.